Investment
Features
FeesSafety
Academy
More
Pluang+

Compare British American Tobacco PLC (BTI) vs Revvity Inc (RVTY) Price & Performance

British American Tobacco PLCTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

British American Tobacco PLC vs Revvity Inc — how do they compare? British American Tobacco PLC trades at $59.39 (market cap $124.84B), while Revvity Inc trades at $111.64 (market cap $12.41B). The key difference: British American Tobacco PLC is far larger — about 10.1× Revvity Inc's market cap, and British American Tobacco PLC pays the higher dividend (5.74%). Which is the better fit depends on your goals.

BTIRVTY
Market Cap
$124.84B$12.41B
Sector
Consumer StaplesTechnology
52-Week High
$66.70$117.75
52-Week Low
$50.39$82.26
Enterprise Value
$166.06B$14.90B
Dividend Yield
5.74%0.25%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

British American Tobacco PLC

British American Tobacco (BTI) trades at $58.95, down 1.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 30.32% net income margin and attractive valuation at 12.79 P/E ratio. Recent earnings show beats in Q2 and Q4 2025, though Q4 2024 missed expectations. The company is undergoing restructuring with 5,500 job cuts announced in June 2026 to streamline operations and reduce costs.

BTI presents a compelling value opportunity with strong dividend yield and improving earnings trajectory, though facing regulatory headwinds and declining cigarette volumes. The stock's current valuation appears attractive relative to historical levels, supported by robust cash flow generation and strategic pivot toward smoke-free products. Key risks include ongoing regulatory pressures and consumer shift away from traditional tobacco products.

Revvity Inc

RVTY trades at $111.11, down 1.05% today, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $1.06 exceeding expectations. Recent developments include AI integration with Anthropic's Claude and FDA clearance for a testosterone assay, signaling innovation in diagnostics and life sciences.

The outlook remains positive with strong analyst support (51.72% buy ratings) and a consensus price target of $111.43. Key risks include margin pressure from China divestment plans and weak academic demand. Revenue stability around $2.9B supports valuation, though high P/E of 53.47 requires sustained growth to justify.

Returns comparison

Trailing returns across standard periods

About British American Tobacco PLC

Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.

Read more on BTI

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY